Compare · BDX vs WOK
BDX vs WOK
Side-by-side comparison of Becton Dickinson and Company (BDX) and WORK Medical Technology Group LTD (WOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and WOK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $42.57B, about 1272244.5x WOK ($33,457).
- Over the past year, BDX is down 12.0% and WOK is down 100.0% - BDX leads by 88.0 points.
- BDX has hit the wire 4 times in the past 4 weeks while WOK has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for WOK).
- Company
- Becton Dickinson and Company
- WORK Medical Technology Group LTD
- Price
- $154.43-2.36%
- $1.96-4.39%
- Market cap
- $42.57B
- $33,457
- 1M return
- +9.01%
- -54.94%
- 1Y return
- -11.95%
- -100.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest WOK
- Large owner Hrt Financial Lp bought $40,501 worth of shares (880,456 units at $0.05) and sold $528,894 worth of shares (136,665 units at $3.87), decreasing direct ownership by 68% to 123,944 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $25,548 worth of shares (268,927 units at $0.10) and sold $168,465 worth of shares (2,904,567 units at $0.06), decreasing direct ownership by 87% to 391,456 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $3,849 worth of shares (48,108 units at $0.08), increasing direct ownership by 2% to 3,027,096 units (SEC Form 4)
- WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
- Large owner Hrt Financial Lp bought $363,500 worth of shares (3,794,711 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 949,661 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $363,617 worth of shares (3,463,022 units at $0.10), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $239,679 worth of shares (2,261,118 units at $0.11), increasing direct ownership by 586% to 2,647,299 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $148,922 worth of shares (1,424,537 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 331,652 shares (SEC Form 3)